US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

0.8180

+0.02443.07%

Post-market: 0.84430.0263+3.22%19:46 EDT

Volume:583.53K

Turnover:476.37K

Market Cap:69.97M

PE:-0.49

High:0.8550

Open:0.8000

Low:0.7707

Close:0.7936

52wk High:2.18

52wk Low:0.6940

Shares:85.54M

Float Shares:61.08M

Volume Ratio:0.75

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6800

EPS(LYR):-1.9600

ROE:-96.42%

ROA:-21.02%

PB:6.86

PE(LYR):-0.42

Loading ...

Overview Company News Filings

Rein Therapeutics - Enrolling Patients in Phase 2 Renew Trial for Lti-03; Interim Data Expected H2 2026

THOMSON REUTERS

Rein Therapeutics Receives U.S. FDA Fast Track Designation for Lti-03 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Rein Therapeutics Releases Corporate Presentation on LTI-03 Idiopathic Pulmonary Fibrosis Program

Rein Therapeutics Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Rein Therapeutics Inc Q2 Income from Operations USD -6.076 Million

THOMSON REUTERS

Rein Therapeutics Inc Q2 Net Income USD -6.375 Million

THOMSON REUTERS

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Rein Therapeutics Q2 FY26 Net Loss Narrows to $6.38 Million; Operating Loss Improves 11.57% to $6.08 Million

Rein Therapeutics Inc Expected to Post a Loss of 17 Cents a Share - Earnings Preview

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rein Therapeutics Publishes First-in-Human LTI-03 Idiopathic Pulmonary Fibrosis Data in Nature Communications

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Rein Therapeutics Holds Annual Shareholder Meeting

Rein Therapeutics Releases Update on Phase 2 RENEW Trial Enrollment Expansion

Rein Therapeutics Announces Phase 2 Renew Trial NOW Enrolling Across All Five Countries

THOMSON REUTERS

Rein Therapeutics initiated with a Buy at Maxim

Rein Therapeutics Inc : Maxim Group Initiates Coverage with Buy Rating; Price Target $4

THOMSON REUTERS

Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK

Rein Therapeutics Expands Phase 2 Renew Trial Into United Kingdom

THOMSON REUTERS

Kymera Therapeutics names Penny Carlson SVP, Development Operations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/RNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":0.818,"timestamp":1787342400000,"preClose":0.7936,"halted":0,"volume":583528,"hourTrading":{"tag":"盘后","latestPrice":0.844335,"preClose":0.818,"latestTime":"19:46 EDT","volume":7545,"amount":6175.739155,"timestamp":1787356011807,"change":0.026335,"changeRate":0.032194,"amplitude":0.077628},"delay":0,"changeRate":0.030745967741935457,"floatShares":61080100,"shares":85539032,"eps":-1.68,"marketStatus":"Market Closed","change":0.0244,"latestTime":"08-21 16:00:00 EDT","open":0.8,"high":0.855,"low":0.77065,"amount":476368.0136116,"amplitude":0.106288,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.68,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":0.7936,"preHourTrading":{"tag":"盘前","latestPrice":0.81,"preClose":0.7936,"latestTime":"09:16 EDT","volume":3748,"amount":3020.7776214,"timestamp":1787318177272,"change":0.0164,"changeRate":0.020665,"amplitude":0.035534},"postHourTrading":{"tag":"盘后","latestPrice":0.844335,"preClose":0.818,"latestTime":"19:46 EDT","volume":7545,"amount":6175.739155,"timestamp":1787356011807,"change":0.026335,"changeRate":0.032194,"amplitude":0.077628},"volumeRatio":0.7519483352709723},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":61080100,"roa":"-21.02%","roe":"-96.42%","lyrEps":-1.959999,"volumeRatio":0.7519483352709723,"shares":85539032,"dividePrice":0,"high":0.855,"amplitude":0.106288,"preClose":0.7936,"low":0.77065,"week52Low":0.694,"pbRate":"6.86","week52High":2.18,"institutionHeld":0,"latestPrice":0.818,"eps":-1.68,"divideRate":0,"volume":583528,"delay":0,"ttmEps":-1.68,"open":0.8,"prevYearClose":1.16,"prevWeekClose":0.806,"prevMonthClose":0.7374,"prevQuarterClose":1.04,"fiveDayClose":0.806,"twentyDayClose":0.7913,"sixtyDayClose":1.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"RNTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2026-05-15","symbol":"RNTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2026-03-26","symbol":"RNTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-14","symbol":"RNTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-08-14","symbol":"RNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.22,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2026-08-21","current":-0.486905,"percent":0.279302,"low":-2.05691,"twenty":-1.502634,"median":-0.637436,"eighty":-0.517826,"high":-0.401342,"avg":-0.920644,"sd":0.504006,"marketCap":67883775},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-08","current":-0.417509,"twenty":-1.496707,"median":-0.703515,"eighty":-0.543648,"marketCap":25581194},{"date":"2025-08-15","current":-0.434435,"twenty":-1.490779,"median":-0.698131,"eighty":-0.532953,"marketCap":26618269},{"date":"2025-08-22","current":-0.445213,"twenty":-1.481888,"median":-0.696336,"eighty":-0.524276,"marketCap":26334772},{"date":"2025-08-29","current":-0.445213,"twenty":-1.478924,"median":-0.689114,"eighty":-0.516321,"marketCap":26334772},{"date":"2025-09-05","current":-0.537801,"twenty":-1.474478,"median":-0.673872,"eighty":-0.514875,"marketCap":31811472},{"date":"2025-09-12","current":-0.425513,"twenty":-1.472996,"median":-0.650825,"eighty":-0.513429,"marketCap":25169516},{"date":"2025-09-19","current":-0.453092,"twenty":-1.467069,"median":-0.643512,"eighty":-0.506198,"marketCap":26800874},{"date":"2025-09-26","current":-0.470822,"twenty":-1.467069,"median":-0.629523,"eighty":-0.496939,"marketCap":27849604},{"date":"2025-10-03","current":-0.457032,"twenty":-1.465587,"median":-0.622528,"eighty":-0.470507,"marketCap":27033925},{"date":"2025-10-10","current":-0.539771,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"marketCap":31927997},{"date":"2025-10-17","current":-0.504312,"twenty":-1.455213,"median":-0.601544,"eighty":-0.470507,"marketCap":29830538},{"date":"2025-10-24","current":-0.496432,"twenty":-1.437431,"median":-0.598047,"eighty":-0.472004,"marketCap":29364436},{"date":"2025-10-31","current":-0.61069,"twenty":-1.435949,"median":-0.596299,"eighty":-0.477169,"marketCap":36122917},{"date":"2025-11-07","current":-0.61463,"twenty":-1.430022,"median":-0.598047,"eighty":-0.479267,"marketCap":36355968},{"date":"2025-11-14","current":-0.531891,"twenty":-1.430022,"median":-0.598047,"eighty":-0.480672,"marketCap":31461895},{"date":"2025-11-21","current":-0.616035,"twenty":-1.42854,"median":-0.59455,"eighty":-0.480672,"marketCap":36275207},{"date":"2025-11-28","current":-0.700851,"twenty":-1.422612,"median":-0.598047,"eighty":-0.480672,"marketCap":41269619},{"date":"2025-12-05","current":-0.620499,"twenty":-1.415203,"median":-0.603206,"eighty":-0.482843,"marketCap":36538070},{"date":"2025-12-12","current":-0.687459,"twenty":-1.415203,"median":-0.607107,"eighty":-0.492492,"marketCap":40481028},{"date":"2025-12-19","current":-0.575859,"twenty":-1.407793,"median":-0.606928,"eighty":-0.496432,"marketCap":33909432},{"date":"2025-12-26","current":-0.589251,"twenty":-1.390011,"median":-0.606928,"eighty":-0.496432,"marketCap":34698024},{"date":"2026-01-02","current":-0.517826,"twenty":-1.341109,"median":-0.603755,"eighty":-0.496432,"marketCap":30492203},{"date":"2026-01-09","current":-0.54461,"twenty":-1.311471,"median":-0.601544,"eighty":-0.497777,"marketCap":32069386},{"date":"2026-01-16","current":-0.517826,"twenty":-1.30258,"median":-0.596299,"eighty":-0.498849,"marketCap":30492203},{"date":"2026-01-23","current":-0.598179,"twenty":-1.296652,"median":-0.593762,"eighty":-0.499215,"marketCap":35223751},{"date":"2026-01-30","current":-0.638355,"twenty":-1.293688,"median":-0.598047,"eighty":-0.499741,"marketCap":37589526},{"date":"2026-02-06","current":-0.508898,"twenty":-1.277387,"median":-0.593762,"eighty":-0.500131,"marketCap":29966475},{"date":"2026-02-13","current":-0.52229,"twenty":-1.259605,"median":-0.589251,"eighty":-0.501948,"marketCap":30755066},{"date":"2026-02-20","current":-0.49997,"twenty":-1.259605,"median":-0.58056,"eighty":-0.49997,"marketCap":29440747},{"date":"2026-02-27","current":-0.535682,"twenty":-1.255159,"median":-0.578693,"eighty":-0.50005,"marketCap":31543658},{"date":"2026-03-06","current":-0.531218,"twenty":-1.154976,"median":-0.575859,"eighty":-0.50116,"marketCap":31280794},{"date":"2026-03-13","current":-0.571395,"twenty":-0.81895,"median":-0.571395,"eighty":-0.504312,"marketCap":33646568},{"date":"2026-03-20","current":-0.580323,"twenty":-0.79198,"median":-0.575859,"eighty":-0.504312,"marketCap":34172296},{"date":"2026-03-27","current":-0.566931,"twenty":-0.783866,"median":-0.57248,"eighty":-0.504336,"marketCap":33383705},{"date":"2026-04-02","current":-0.6803,"twenty":-0.771713,"median":-0.575859,"eighty":-0.504434,"marketCap":33927228},{"date":"2026-04-10","current":-0.860214,"twenty":-0.793249,"median":-0.580323,"eighty":-0.506198,"marketCap":42899718},{"date":"2026-04-17","current":-0.955793,"twenty":-0.871458,"median":-0.580323,"eighty":-0.506198,"marketCap":47666354},{"date":"2026-04-24","current":-1.034505,"twenty":-0.955793,"median":-0.58056,"eighty":-0.506198,"marketCap":51591818},{"date":"2026-05-01","current":-0.761823,"twenty":-0.933304,"median":-0.589251,"eighty":-0.508898,"marketCap":37992888},{"date":"2026-05-08","current":-1.830837,"twenty":-0.955793,"median":-0.589251,"eighty":-0.508898,"marketCap":91305667},{"date":"2026-05-15","current":-1.768244,"twenty":-1.034505,"median":-0.593762,"eighty":-0.508898,"marketCap":88184106},{"date":"2026-05-22","current":-1.771841,"twenty":-1.259605,"median":-0.598047,"eighty":-0.508898,"marketCap":88960593},{"date":"2026-05-29","current":-2.05691,"twenty":-1.290724,"median":-0.598179,"eighty":-0.508898,"marketCap":103273325},{"date":"2026-06-05","current":-1.890133,"twenty":-1.32629,"median":-0.602094,"eighty":-0.50963,"marketCap":94899812},{"date":"2026-06-12","current":-1.715203,"twenty":-1.416685,"median":-0.60675,"eighty":-0.511716,"marketCap":86116928},{"date":"2026-06-18","current":-1.602722,"twenty":-1.430022,"median":-0.607107,"eighty":-0.512192,"marketCap":80469458},{"date":"2026-06-26","current":-1.733363,"twenty":-1.459659,"median":-0.611131,"eighty":-0.512894,"marketCap":87028710},{"date":"2026-07-02","current":-1.812304,"twenty":-1.467069,"median":-0.615082,"eighty":-0.513362,"marketCap":90992173},{"date":"2026-07-10","current":-1.848995,"twenty":-1.481888,"median":-0.616035,"eighty":-0.513362,"marketCap":92834346},{"date":"2026-07-17","current":-1.597348,"twenty":-1.504116,"median":-0.61855,"eighty":-0.513362,"marketCap":80199645},{"date":"2026-07-24","current":-1.482643,"twenty":-1.518935,"median":-0.622528,"eighty":-0.513389,"marketCap":74440529},{"date":"2026-07-31","current":-1.423159,"twenty":-1.517453,"median":-0.62645,"eighty":-0.513429,"marketCap":71453976},{"date":"2026-08-07","current":-1.343362,"twenty":-1.510044,"median":-0.629957,"eighty":-0.513969,"marketCap":67447526},{"date":"2026-08-14","current":-1.341658,"twenty":-1.504116,"median":-0.633891,"eighty":-0.51647,"marketCap":67361987},{"date":"2026-08-21","current":-1.364196,"twenty":-1.502634,"median":-0.637436,"eighty":-0.517826,"marketCap":67883775}],"updateTime":1787524957370},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660819432","title":"Rein Therapeutics - Enrolling Patients in Phase 2 Renew Trial for Lti-03; Interim Data Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660819432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660819432?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:00","pubTimestamp":1787227200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABJGYW7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660281613","title":"Rein Therapeutics Receives U.S. FDA Fast Track Designation for Lti-03 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2660281613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660281613?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:00","pubTimestamp":1787227200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABJGYW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660209804","title":"Rein Therapeutics Releases Corporate Presentation on LTI-03 Idiopathic Pulmonary Fibrosis Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2660209804","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660209804?lang=en_us&edition=fundamental","pubTime":"2026-08-20 02:42","pubTimestamp":1787164961,"startTime":"0","endTime":"0","summary":"Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis programRein Therapeutics highlighted lead inhaled peptide LTI-03 for idiopathic pulmonary fibrosis, now in Phase 2 with an interim readout expected in 2026.Phase 1b met its primary endpoint; high-dose 5 mg twice daily was well tolerated with no identified safety issues.Program showed biomarker shifts linked to lung health, including a 5% decrease in surfactant protein D over two weeks at 5 mg.Management framed LTI-03 as a multi-pathway caveolin-1 scaffolding domain mimic with antifibrotic activity, alongside signals of epithelial cell support.Pipeline update flagged LTI-01 for loculated pleural effusions as Phase 2b-ready, with development temporarily delayed to prioritize LTI-03.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3kRgnH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659455581","title":"Rein Therapeutics Inc Reports Results for the Quarter Ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659455581","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659455581?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:13","pubTimestamp":1786706029,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRein Therapeutics IncRNTX.OQreported a quarterly adjusted loss of 19 cents per share for the quarter ended March ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659518143","title":"Rein Therapeutics Inc Q2 Income from Operations USD -6.076 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659518143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659518143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:44","pubTimestamp":1786704273,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLXSMHMRW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143517","title":"Rein Therapeutics Inc Q2 Net Income USD -6.375 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143517?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:44","pubTimestamp":1786704273,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLXSMHMRW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143510","title":"Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143510?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:44","pubTimestamp":1786704273,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA59SG83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659480081","title":"Rein Therapeutics Q2 FY26 Net Loss Narrows to $6.38 Million; Operating Loss Improves 11.57% to $6.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659480081","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659480081?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:35","pubTimestamp":1786703720,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Q2 FY26 net loss narrows to $6.38 million; operating loss improves 11.57% to $6.08 millionRein Therapeutics posted a net loss of USD 6.38 million for the quarter ended June 30, 2026,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4Bnkpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658195175","title":"Rein Therapeutics Inc Expected to Post a Loss of 17 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658195175","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658195175?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:41","pubTimestamp":1786394466,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc <RNTX.OQ> expected to post a loss of17cents a share - Earnings PreviewRein Therapeutics IncRNTX.OQRNTX.Ois expected to  show no change in quarterly revenue when it reports  results on August 12  for the period ending June 30 2026LSEG's mean analyst estimate for Rein Therapeutics Inc is for a loss of 17 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Rein Therapeutics Inc is $6.00, about 633.9% above its last closing price of $0.82This summary was machine generated August 10 at 20:41 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4471XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657527689","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657527689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657527689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:40","pubTimestamp":1785958806,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verano Holdings (VRNO) and Rein Therapeutics (RNTX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-281?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-281?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNTX","BK4139","VRNO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559825","title":"Rein Therapeutics Publishes First-in-Human LTI-03 Idiopathic Pulmonary Fibrosis Data in Nature Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559825?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:07","pubTimestamp":1785845236,"startTime":"0","endTime":"0","summary":"Rein Therapeutics publishes first-in-human LTI-03 idiopathic pulmonary fibrosis data in Nature CommunicationsRein Therapeutics reported peer-reviewed publication of first-in-human LTI-03 data in Natur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4kXFSr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","BCDF","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","RNTX","BK4139","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556464","title":"Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556464","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556464?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"Data support ongoing Phase 2 “RENEW” trialFirst-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patientsStudy confirms LTI-03 was sa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338229/28652/en/Rein-Therapeutics-Announces-Publication-of-Landmark-LTI-03-Clinical-Data-in-Nature-Communications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07766","TSLZ","CRSH","TSLS","TSLO","TSLR","BK4007","TEST","FVC","TESL","TSLP","BK4139","TSL","LARK","TSLY","BK4211","TLA","TSLT","TSDD","07366","TSLI","TSYY","BK4539","LENZ","TSLW","09366","TSLQ","TSII","TSLG","TSLL","09766","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653924788","title":"Rein Therapeutics Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653924788","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653924788?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:12","pubTimestamp":1784664742,"startTime":"0","endTime":"0","summary":"Rein Therapeutics holds annual shareholder meetingRein Therapeutics held its 2026 annual shareholder meeting on July 20, 2026.Shareholders backed a charter amendment raising authorized common shares t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL2z9jCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653247272","title":"Rein Therapeutics Releases Update on Phase 2 RENEW Trial Enrollment Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2653247272","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653247272?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:04","pubTimestamp":1784635478,"startTime":"0","endTime":"0","summary":"Rein Therapeutics releases update on Phase 2 RENEW trial enrollment expansionRein Therapeutics posted a press release stating its Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL5bGNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","BK4139","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","RNTX","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272975","title":"Rein Therapeutics Announces Phase 2 Renew Trial NOW Enrolling Across All Five Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653272975?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA7BS3Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652921820","title":"Rein Therapeutics initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2652921820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652921820?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:45","pubTimestamp":1784547911,"startTime":"0","endTime":"0","summary":"Maxim initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $4 price target Published first on TheFly – the ultimate source for real...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218528","title":"Rein Therapeutics Inc : Maxim Group Initiates Coverage with Buy Rating; Price Target $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218528?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:41","pubTimestamp":1784547719,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642811062","title":"Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2642811062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642811062?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:02","pubTimestamp":1781179367,"startTime":"0","endTime":"0","summary":"Rein Therapeutics expanded its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis into the U.K.No study results were presented; the update focused on trial execution and enrollment progress.The first U.K. patient was randomized; 16 patients have been enrolled across the study to date.Sites are enrolling in the U.S., Australia, and the U.K., supporting a broader international footprint for the program.Two additional countries are expected to be added in coming months, signaling continued scale-up of the Phase 2 development plan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLbPRBxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","RNTX","LU2210149790.SGD","BK4112","NDAQ","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281684","title":"Rein Therapeutics Expands Phase 2 Renew Trial Into United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281684?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA8QXW0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431386","title":"Kymera Therapeutics names Penny Carlson SVP, Development Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431386","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431386?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:01","pubTimestamp":1780948885,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics appointed Penny Carlson as senior vice president, development operations to lead global clinical development operations for its oral immunology portfolio.Carlson previously served as vice president and head of global clinical development operations at Takeda, overseeing planning and execution of clinical trials.She earlier held leadership roles at Millennium Pharmaceuticals, Aileron Therapeutics, and other drugmakers.Chief Operating Officer Jeremy Chadwick will retire, remaining an adviser through year-end.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9RPdD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","KYMR","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","RNTX","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}